



Combined Form PTO/SB/08A&B INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	10/584,415
		Confirmation Number	9423
		Filing Date	June 26, 2006
		First Named Inventor	Yasuomi URANO et al.
		Art Unit	1614
		Examiner Name	Unknown L. Royds
Sheet	1	of	2
		Attorney Docket Number	062522

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	1	US 3,983,140		09-28-1976	Endo et al.
	2	US 5,231,938		11-04-1980	Monaghan et al.
	3	US 4,346,227		08-24-1982	Terahara et al.
	4	US 4,444,784		04-24-1984	Hoffman et al.
	5	US 5,177,080	A	01-05-1993	Angerbauer et al.
	6	US 5,260,440	A	11-09-1993	Hirai et al.
	7	US 5,273,995	A	12-28-1993	Roth
	8	US 5,354,772	A	10-11-1994	Kathawala
	9	US 5,856,336	A	01-05-1999	Fujikawa et al.
	10	US 6,080,778	A	06-27-2000	Yankner et al.
	11	US 6,440,387	B1	08-27-2002	Yankner et al.
	12	US 6,472,421	B1	10-29-2002	Wolozin

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
	13	WO	00/28981	A2	05-25-2000	Nymox Corporation	
	14	WO	01/32161	A2	05-10-2001	Andrx Corporation	
	15	WO	01/96311	A2	12-20-2001	Bristol-Myers Squibb Company	
	16	WO	02/062824	A2	08-15-2002	Andrx Corporation	
	17	WO	99/48488	A2	09-30-1999	Children's Medical Center Corporation	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (10/22/2008)

/Leslie A. Royds/ (10/22/2008)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
	18	Robert L. Nussbaum, M.D. et al., "Alzheimer's Disease and Parkinson's Disease", The New England Journal of Medicine, April 3, 2003, page 1356-1364.	
	19	Kai Simons et al., "Cholesterol, lipid rafts, and disease", The Journal of Clinical Investigation, September 2002, vol. 110, page 597-603.	
	20	B. Wolozin, "Cholesterol and Alzheimer's disease", Biochemical Society Transactions, 2002, vol. 30, page 252-529.	
	21	George H. Rothblat et al., "Cell cholesterol efflux: integration of old and new observations provides new insights", Journal of Lipid Research, 1999, vol. 40, page 781-796.	
	22	Suzanne Wahrle et al., "Cholesterol-Dependent γ -Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains", Neurobiology of Disease, 2002, vol. 9, page 11-23.	
	23	Satoko Wada et al., " γ -Secretase Activity Is Present in Rafts but Is Not Cholesterol-Dependent", Biochemistry, 2003, vol. 42, Page 13977-13986.	
	24	Andrea Tedde et al., "Identification of New Presenilin Gene Mutations in Early-Onset Familial Alzheimer Disease", Arch Neurol, November 2003, vol. 60, page 1541-1544	
	25	Susan B. Roberts, " γ -Secretase inhibitors and Alzheimer's disease", Advanced Drug Delivery Reviews, 20020, vol. 54, page 1579-1588.	
	26	Craig A. Micchelli et al., " γ -Secretase / presenilin inhibitors for Alzheimer's disease phenocopy <i>Notch</i> mutations in <i>Drosophila</i> ", The FASEB Journal, January 2003, vol. 17, page 79-81.	
	27	Yasuko Takahashi et al., "Sulindac Sulfide Is a Noncompetitive γ -Secretase Inhibitor That Preferentially Reduces A β 42 Generation", The Journal of Biological Chemistry, May 16, 2003, vol. 278, No. 20, page 18664-18670.	
	28	Sascha Weggen et al., "A β 42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage if the Amyloid Precursor Protein (APP) and ErbB-4 Receptor Signaling through the APP intracellular Domain", The Journal of Biological Chemistry, August 15, 2003, vol. 278, No. 33, page 30748-30754.	
	29	Yan Zhou et al. "Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic A β 42 by Inhibition Rho", Science, November 14, 2003, vol. 302, page 1215-1217.	
	30	Michael D. Greenspan et al., "Inhibition of hydroxymethylglutaryl-coenzyme A synthase by L-659,699", Proc. Natl. Acad. Sci. USA, 1987, vol. 84, page 7488-7492.	
	31	Cheryl J. Hemingway et al., "Gemfibrozil activation of AMP-activated protein kinase", S676 Biochemical Society Transactions, 1997, page 2.	
	32	Ermond van Beek, "Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates", Biochemical and Biophysical Research Communications, 1999, vol. 264, page 108-111.	
	33	Takashi Sakurai et al., "Amyloid precursor protein and lipid rafts", 2003, vol. 54, No. 4, page 291-296.	

Examiner Signature	/Leslie A. Royds/ (10/22/2008)	Date Considered	
--------------------	--------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (10/22/2008)